glp-1 and substance use disorder MSN GLP-1 Receptor Agonists Show Promise

Yes, but only under prescriber guidance

Kostoff RN, Briggs MB, Porter AL, Aschner M, Spandidos DA, Tsatsakis A

These requirements mirror those that may have limited adoption of Rybelsus, the oral semaglutide from Novo Nordisk approved for diabetes in 2019. One challenge in developing oral versions of semaglutide is that the drug is based on chains of amino acids known as peptides which are subject to degradation by enzymes in the stomach. In contrast, Eli Lillys upcoming oral GLP1 candidate, orforglipron, is a smallmolecule drug rather than a peptide, which could lessen the need for dosing requirements and offer greater convenience to users. This ease of use has fueled expectations of growing market share for oral GLP-1 formulations, with analysts estimating they could generate $22 billion annually by 2030, capturing 24% of the global weight loss market. For plan sponsors, the arrival of oral options means usage could grow, reinforcing the need for comprehensive utilization-management strategies

Are all generic semaglutide brands equally effective

The calibration range covered 20.05000 ng/mL in human plasma and 0.10020.0 g/mL in human urine